NEUMORA THERAPEUTICS, INC. Accretion Expense
NEUMORA THERAPEUTICS, INC. (NMRA) reported Accretion Expense of $261.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-08-14
- NEUMORA THERAPEUTICS, INC. accretion expense for the quarter ending 2026-06-30 was $261.00K, a 506.98% increase year-over-year.
- NEUMORA THERAPEUTICS, INC. accretion expense for the quarter ending 2026-03-31 was $287.00K.
- NEUMORA THERAPEUTICS, INC. accretion expense for the quarter ending 2025-06-30 was $43.00K.
- NEUMORA THERAPEUTICS, INC. accretion expense for fiscal 2025 was $336.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $261.00K 10-Q · filed 2026-08-14 | $548.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $287.00K 10-Q · filed 2026-05-07 | ||
| 2025-12-31 | $336.00K 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $43.00K 10-Q · filed 2026-08-14 | $43.00K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |